Optimizing the Clinical Utility of Biomarkers in Oncology: The NCCN Biomarkers Compendium.
review · Level V
Where this comes from
- Record sourced from PubMed, PMID 25333835.
- Also identified by DOI 10.5858/arpa.2014-0146-RA.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
The rapid development of commercial biomarker tests for oncology indications has led to confusion about which tests are clinically indicated for oncology care. By consolidating biomarker testing information recommended within National Comprehensive Cancer Network Clinical Practice Guidelines in Oncology (NCCN Guidelines), the NCCN Biomarkers Compendium aims to ensure that patients have access to appropriate biomarker testing based on the evaluations and recommendations of the expert NCCN panel members. To present the recently launched NCCN Biomarkers Compendium. Biomarker testing information recommended within NCCN Clinical Treatment Guidelines as well as published resources for genetic and biological information. The NCCN Biomarkers Compendium is a continuously updated resource for clinicians who need access to relevant and succinct information about biomarker testing in oncology and is linked directly to the recommendations provided within the NCCN Clinical Practice Guidelines.
Medical subject headings
- Biomarkers, Tumor
- Medical Oncology